The therapy for opioid-induced constipation has no restrictions on an unidentified national formulary that serves these Blues plans.
RedHill Biopharma, a specialty biopharmaceutical company in Raleigh, N.C., has received Preferred Brand status on a unidentified national formulary that serves some Blue Cross plans for Movantik (naloxegol), a treatment for opioid-induced constipation. The coverage started on July 1, 2021.
“This important new listing as an unrestricted preferred brand strengthens Movantik’s leadership position and now means that over 30 million more Americans will have access to Movantik,” Rick Scruggs, RedHill’s chief commercial officer, said in a statement.
Company officials said Movantik’s total commercial coverage now extends to 152 million American patients’ lives.
The FDA approved Movantik in September 2014. RedHill acquired global marketing rights (except in Europe and Canada) to Movantik from AstraZeneca in April 2020.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More